Tuberculosis treatment failure and drug resistance - Same strain or reinfection?

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 6, 2000, Pages 603-607

  Sonnenberg, Pamela ^a   Murray, Jill ^b   Shearer, Stuart ^c   Glynn, Judith R ^a   Kambashi, Bupe ^d   Godfrey Faussett, Peter ^a,d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c GOLD FIELDS LIMITED   (South Africa)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

DNA fingerprinting; Drug resistance; Miners; Mycobacterium tuberculosis; South Africa; Treatment failure; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BACTERIUM TRANSFORMATION; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DNA FINGERPRINTING; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LABORATORY TEST; MAJOR CLINICAL STUDY; MINER; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REINFECTION; SOUTH AFRICA; SPUTUM CULTURE; STRAIN DIFFERENCE; TREATMENT FAILURE; TUBERCULOSIS;

EID: 0033653268     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90205-0     Document Type: Article

References (36)

1. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire
2. False-positive results from cultures of Mycobacterium tuberculosis due to laboratory cross-contamination confirmed by restriction fragment length polymorphism
3. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family
4. Retrospective detection of laboratory cross-contamination of Mycobacterium tuberculosis cultures with use of DNA fingerprint analysis
5. The incidence of false-positive cultures for Mycobacterium tuberculosis
6. Stability of DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis
7. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993
8. Mycobacterial disease in South African gold miners in the era of HIV infection
9. Drug-resistant tuberculosis in South African gold miners: Incidence and associated factors
10. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
11. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus
12. Analysis of rate of change of IS6110 RFLP patterns of Mycobacterium tuberculosis based on serial patient isolates
13. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues
14. Transmission of multidrug-resistant tuberculosis in a large urban setting
15. Resurgence of tuberculosis and the impact of HIV infection
16. Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malawi
17. DNA fingerprints of Mycobacterium tuberculosis do not change during the development of rifampicin resistance
18. Tuberculosis control and molecular epidemiology in a southern African gold mining community
19. Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant Mycobacterium tuberculosis
20. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa
21. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana
22. The global tuberculosis situation and the new control strategy of the World Health Organization
23. Impact of short-course therapy on tuberculosis drug resistance in southwest Burkina Faso
24. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis
25. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients
26. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection
27. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months
28. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
29. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: A molecular epidemiologic assessment
30. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
31. The effect of dosage cards on compliance with directly observed tuberculosis therapy in hospital
32. Strain identification of Mycobacterium tuberculosis by DNA finger-printing: Recommendations for a standardized methodology
33. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling 'Strain W' among noninstitutionalized, human immunodeficiency virus-seronegative patients
34. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment
35. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis
36. Resistance to antituberculosis drugs in rural South Africa: Rates, patterns, risks, and transmission dynamics